Neutral Rating Was Issued By Broker For Calyxt (CLXT)

September 8, 2018 - By Victoria Pittman

How Goldman Sachs Currently Rates Calyxt (CLXT)

In an analyst report revealed to clients on Friday, 7 September, equity research analysts at Goldman Sachs initiated coverage on Calyxt (CLXT) shares. The company issued a key Neutral rating for CLXT stock.

The stock decreased 5.53% or $0.96 during the last trading session, reaching $16.41. About 144,522 shares traded or 75.29% up from the average. Calyxt, Inc. (CLXT) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Calyxt, Inc. (NASDAQ:CLXT) to report earnings on November, 12. They expect $-0.28 EPS, up 45.10 % or $0.23 from last year’s $-0.51 per share. After $-0.25 actual EPS reported by Calyxt, Inc. for the previous quarter, Wall Street now forecasts 12.00 % negative EPS growth.

Calyxt, Inc., an agriculture biotechnology company, develops healthier specialty food ingredients and agricultural food crops using gene editing technology for plants. The company has market cap of $530.80 million. It engages in the development of high oleic soybeans, powdery mildew resistant wheat, cold storable potatoes, high fiber wheat, reduced browning potatoes, and herbicide tolerant wheat. It currently has negative earnings. The Firm was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015.

More news for Calyxt, Inc. (NASDAQ:CLXT) were recently published by: Seekingalpha.com, which released: “Calyxt names Dr. Yves J. Ribeill as Interim CEO” on August 22, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on September 07, 2018 is yet another important article.

Calyxt, Inc. (NASDAQ:CLXT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.